Abstract: RESULTS: Forty out of the 120 patients were found to have one or two point mutations associated with drug resistance, including 17 with L180M and M204V/I mutations (42.5%), 10 with M204V/I mutation (25%), 8 with N236T mutation (20%), 3 with L180M mutation (7.5%), and 1 with both A181V/T and N236T mutations (2.5%), and 1 with A181V/T mutation(2.5%).
The perils of relying on anti-hepatitis B total core antibody in screening individuals infected with HIV.
PMID: 22422696
2012
International journal of STD & AIDS
Abstract: High-grade HBV viraemia associated with L180M and M240V drug-resistance mutations was confirmed.
Convergence and coevolution of hepatitis B virus drug resistance.
Introduction: Other mutations that have been reported to be associated with lamivudine resistance include rtA181V/T and several secondary RT mutations, for example, rtV173L and rtL180M.
Result: Besides the sites for the primary (rtM204V/I) and secondary (rtL180M) lamivudine-resistance mutations identified in five patients, only one additional site with significant changes in intra-host populations was shared by HBV in three patients and four sites by HBV in two patients.
Result: In Patient 6, one major post-treatment HBV variant differed from the major pre-treatment variant by only
Simultaneous emergence of entecavir resistance mutations in a nucleoside-naive chronic hepatitis B patient.
Abstract: The ETV resistance-related substitution (T184A) and lamivudine resistance-related substitutions (L180M and M204V) were detected by sequence analysis at week 96.
Ultra-deep pyrosequencing detects conserved genomic sites and quantifies linkage of drug-resistant amino acid changes in the hepatitis B virus genome.
Abstract: On linkage analysis of the RT region studied, NA-resistant HBV variants (except for rtA181T) were present in combinations of amino acid substitutions that increased in complexity after viral breakthrough to entecavir, at which time the combined variant rtL180M-S202G-M204V-V207I predominated.
Result: Among them, combined variants carrying only LMV resistant mutations, such as rtV173L-rtL180M-rtM204V and rtL180M- PMID: 22672436
2012
BMC microbiology
Introduction: Compensatory mutations in the rt domain (rtL180M, rtV173L, rtL80I/V) that partially restore replication efficiency are often co-selected in HBV rt204 mutants.
A multicentre molecular analysis of hepatitis B and blood-borne virus coinfections in Viet Nam.
Result: 78.9% (n = 15/19) of these individuals had undetectable HBV viral loads and, of the 4 patients on HAART with a detectable HBV viral load, one - a HIV/HBV/HCV coinfected IDU - had drug resistance associated mutations, L180M and M204V in the pol gene conferring resistance to lamivudine and possible resistance to telbivudine.
Lamivudine plus adefovir or telbivudine plus adefovir for chronic hepatitis B patients with suboptimal response to adefovir.
Abstract: After 12-month treatment, 8.1% (3/37) of patients in group A and 5.7% (2/35) of patients in group B had VR; among patients in group A, two had rtM204V/I and rtL180M and one had rtN236T, whereas the two patients in group B had rtM204I+rtL180M.
YMDD motif mutations in chronic hepatitis B antiviral treatment naive patients: a multi-center study.
PMID: 22729192
2012
The Brazilian journal of infectious diseases
Abstract: YMDD mutation was accompanied by L180M mutation in 154 (76.9%) patients.
A pilot randomized controlled trial of dual-plasmid HBV DNA vaccine mediated by in vivo electroporation in chronic hepatitis B patients under lamivudine chemotherapy.
Abstract: The incidence of dual-site mutations of rtM204/I/S+rtL180M was significantly lower (P = 0.03) with an identified lower virological breakthrough (VBT) rate (P = 0.03) in patients receiving LAM+DNA vaccine than LAM monotherapy, accompanied with a significant higher positive T-cell response rate in patients receiving LAM+DNA vaccine (P = 0.03).
HBV mutation literature information.
PMID: 
2012
Nan fang yi ke da xue xue bao
Browser Board
Co-occurred Entities
Filtrator
ViMRT